Management of lipid variables in primary cardiovascular prevention: A position paper from the Heart, Vessels and Metabolism Group of the French Society of Cardiology

Arch Cardiovasc Dis. 2024 May;117(5):358-378. doi: 10.1016/j.acvd.2024.02.004. Epub 2024 Apr 23.

Abstract

Low-density lipoprotein cholesterol has been established as a powerful cardiovascular risk factor; its reduction provides a clinical benefit in primary cardiovascular prevention, irrespective of the characteristics of the patients treated. It is useful to tailor low-density lipoprotein cholesterol targets according to the magnitude of cardiovascular risk (low, high or very high) in order to reduce the cardiovascular risk as fully as possible. In order to provide a uniform approach, it is necessary to propose recommendations for good practice, defining strategies for reducing low-density lipoprotein cholesterol. It is also necessary to know their merits, to analyse their practical limits and to propose adaptations, taking into account limitations and national specifics. This position paper aims to analyse the contribution and limits, as well as the adaptation to French practice, of 2019 and 2021 European Society of Cardiology recommendations for the management of lipid variables and cardiovascular prevention.

Keywords: Cardiovascular primary prevention; Lipids; Low-density lipoprotein cholesterol.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Biomarkers* / blood
  • Cardiology / standards
  • Cardiovascular Diseases* / blood
  • Cardiovascular Diseases* / diagnosis
  • Cardiovascular Diseases* / prevention & control
  • Cholesterol, LDL* / blood
  • Consensus*
  • Dyslipidemias* / blood
  • Dyslipidemias* / diagnosis
  • Dyslipidemias* / drug therapy
  • Dyslipidemias* / epidemiology
  • Dyslipidemias* / therapy
  • France
  • Heart Disease Risk Factors*
  • Humans
  • Hypolipidemic Agents / therapeutic use
  • Primary Prevention*
  • Risk Assessment
  • Treatment Outcome

Substances

  • Biomarkers
  • Cholesterol, LDL
  • Hypolipidemic Agents